The company also released additional data from its phase 2 clinical trial in addition to the LONGITUDE program design.

Numerous court decisions over the past decade – such as Amgen Inc. v. Sanofi from the US Supreme Court and Juno Therapeutics, Inc. et al. v.

The obesity market was a dominating force in 2024, with GLP-1 medications from Novo Nordisk and Eli Lilly becoming some of ...

2006. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol 18:1759-69.

Glypican 3 (GPC3), a glycosylphosphatidylinositol-anchored heparan sulfate proteoglycan, is expressed in a majority of hepatocellular carcinoma tissues. The murine monoclonal antibody GC33 that ...

The Phase 1a/b trial of ADRX-0405 is taking place at trial sites across the U.S., with first readouts expected in Q4 2025.

Substituting large segments of the mouse antibody molecule with human counterparts means that humanized antibodies have less chance of being recognized as foreign to the body, reducing the risk of ...

Adcentrx begins patient dosing in phase 1a/b study of ADRX-0405, a potential first-in-class ADC targeting STEAP1 to treat advanced solid tumours: San Diego, California Wednesday, ...

Monoclonal Antibodies IndustryThe global monoclonal antibodies (mAbs) industry, valued at USD 186 billion in 2021, is ...

BEIJING & ALAMEDA, Calif. & TAIPEI — Biocytogen (HKEX: 02315) and Acepodia (6976:TT), today announced a groundbreaking ...

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive ...

Mr. Ainsworth brings over two decades of industry and market access experience to Tonix U.S. Food and Drug Administration ...